Yousif Capital Management LLC lowered its holdings in shares of Elevance Health, Inc. (NYSE:ELV - Free Report) by 10.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 35,482 shares of the company's stock after selling 3,965 shares during the period. Yousif Capital Management LLC's holdings in Elevance Health were worth $13,801,000 as of its most recent SEC filing.
Other institutional investors have also recently bought and sold shares of the company. Private Wealth Management Group LLC boosted its stake in Elevance Health by 152.0% during the first quarter. Private Wealth Management Group LLC now owns 63 shares of the company's stock worth $27,000 after buying an additional 38 shares in the last quarter. WPG Advisers LLC acquired a new stake in Elevance Health during the first quarter worth $29,000. North Capital Inc. acquired a new stake in shares of Elevance Health in the 1st quarter valued at $36,000. Saudi Central Bank acquired a new stake in shares of Elevance Health in the 1st quarter valued at $40,000. Finally, Berbice Capital Management LLC acquired a new stake in shares of Elevance Health in the 1st quarter valued at $43,000. Institutional investors and hedge funds own 89.24% of the company's stock.
Elevance Health Stock Performance
Shares of NYSE:ELV opened at $351.43 on Tuesday. The stock has a market capitalization of $79.14 billion, a P/E ratio of 14.95, a P/E/G ratio of 1.29 and a beta of 0.59. Elevance Health, Inc. has a 1-year low of $273.71 and a 1-year high of $510.24. The company has a current ratio of 1.44, a quick ratio of 1.44 and a debt-to-equity ratio of 0.64. The business has a 50-day moving average price of $316.63 and a two-hundred day moving average price of $357.61.
Elevance Health (NYSE:ELV - Get Free Report) last announced its quarterly earnings data on Thursday, July 17th. The company reported $8.84 earnings per share for the quarter, missing the consensus estimate of $9.30 by ($0.46). The firm had revenue of $49.42 billion for the quarter, compared to the consensus estimate of $48.26 billion. Elevance Health had a return on equity of 17.59% and a net margin of 2.83%.The business's revenue for the quarter was up 14.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $10.12 earnings per share. Equities analysts predict that Elevance Health, Inc. will post 33.96 earnings per share for the current year.
Elevance Health Dividend Announcement
The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 25th. Shareholders of record on Wednesday, September 10th were issued a dividend of $1.71 per share. This represents a $6.84 annualized dividend and a yield of 1.9%. The ex-dividend date of this dividend was Wednesday, September 10th. Elevance Health's payout ratio is currently 29.11%.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently commented on ELV shares. Truist Financial reduced their target price on shares of Elevance Health from $500.00 to $440.00 and set a "buy" rating on the stock in a research note on Wednesday, July 16th. Leerink Partnrs downgraded shares of Elevance Health from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Wells Fargo & Company boosted their target price on shares of Elevance Health from $330.00 to $412.00 and gave the company an "overweight" rating in a research note on Tuesday, October 7th. Robert W. Baird reduced their target price on shares of Elevance Health from $492.00 to $297.00 and set a "neutral" rating on the stock in a research note on Friday, July 25th. Finally, JPMorgan Chase & Co. reduced their target price on shares of Elevance Health from $472.00 to $384.00 and set an "overweight" rating on the stock in a research note on Tuesday, July 22nd. Twelve research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $412.00.
Read Our Latest Report on Elevance Health
Insider Activity
In other news, CEO Gail Boudreaux acquired 8,500 shares of the company's stock in a transaction on Friday, July 18th. The stock was purchased at an average cost of $286.94 per share, with a total value of $2,438,990.00. Following the acquisition, the chief executive officer owned 151,020 shares of the company's stock, valued at $43,333,678.80. This trade represents a 5.96% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Susan D. Devore purchased 1,200 shares of the stock in a transaction dated Tuesday, August 19th. The stock was bought at an average cost of $312.15 per share, with a total value of $374,580.00. Following the completion of the purchase, the director owned 3,502 shares in the company, valued at $1,093,149.30. The trade was a 52.13% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 0.29% of the company's stock.
About Elevance Health
(
Free Report)
Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.
Read More
Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc. (NYSE:ELV - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Elevance Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elevance Health wasn't on the list.
While Elevance Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
